← Eichor
Study identifier: NCT06445439 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Optimal Pacing Rate for Cardiac Resynchronization Therapy

Condition: Atrial Fibrillation, Persistent  ·  Sponsor: Medstar Health Research Institute

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.

This description comes directly from the study's public registry record.

Talk to the study team

Sarahfaye Dolman  ·  302-530-1873  ·  Sarahfaye.F.Dolman@medstar.net

Always discuss trial participation with your own doctor first.

Locations (5)

MedStar Georgetown University HospitalWashington D.C., District of Columbia, United StatesRecruiting
MedStar Washington Hospital CenterWashington D.C., District of Columbia, United StatesRecruiting
MedStar Union Memorial HospitalBaltimore, Maryland, United StatesNot Yet Recruiting
MedStar Southern Maryland HospitalClinton, Maryland, United StatesRecruiting
MedStar Heart and Vascular Office at FairfaxFairfax, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06445439